Interview with Ulrich Behrendt, President, VBU
Could you briefly present the Association of German Biotechnology Companies (VBU) and DECHEMA e.V. to our readers and describe their importance to the German biotechnology industry? VBU is a non…
Address: Theodor-Heuss-Allee 25 D – 60486 Frankfurt am Main,Germany
Tel: 069 / 75 64- 124
VBU – Association of German Biotech Companies was founded in October 1996 on the initiative of 55 biotech companies. VBU now has over 210 corporate members, making it the largest and oldest industrial biotechnology association in Germany.Since its foundation VBU has devoted itself to the promotion of science and technology and the transfer of research findings into innovations. Furthermore VBU works in close collaboration with other national and international organisations from the areas of biotechnology, pharma, and knowledge and technology transfer.VBU is part of DECHEMA e.V. which was founded in 1926. Today DECHEMA has over 5,000 personal and sustaining members from science and industry.DECHEMA pools the know-how of experts, provides strong networks for research and development, is a platform for expert information, communication, and practice-oriented exchange of ideas and experience. DECHEMA is at the interface between science, industry, regulatory bodies and the public.
Could you briefly present the Association of German Biotechnology Companies (VBU) and DECHEMA e.V. to our readers and describe their importance to the German biotechnology industry? VBU is a non…
Many companies that are focused in the diabetes segment have recognised the need to strengthen their operations in emerging markets, due to the increased prevalence of the disease in countries…
You joined Cegedim in summer 2006 eleven months before its merger with Dendrite in 2007 that created the world leader in pharmaceutical CRM. How would you describe the integration process…
The acquisition of Jerini has to be one of the biggest milestones for Shire Deutschland in its recent history. How have the synergies developed between the two companies, and how…
You arrived at Grünenthal fairly recently, in January of this year. What was it about the company that attracted you to the position? That goes back to 1987, when I…
Roche, once a true pharmaceutical company, is now recognized by its capacity to create a unique business model that allowed to become the world’s largest biotech company with truly differentiated…
Having experienced many years at big pharmaceutical companies, you recently moved into the booming biotech sector by joining Biogen Idec in 2007. What made you make such a decision? The…
Your father was the founder of Dr. Franz Köhler Chemie – that carries his name – and was a very well respected doctor among the German medical and pharmaceutical community.…
Why was the time right in 2000 to start Paion, and how did your background and experiences in the pharma industry, academia and consulting help you create the successful company…
One of the biggest recent milestones for Hikma’s global operations must have been the acquisition of Ribosepharm and Thymoorgan in 2007. How successfully have the two companies integrated into the…
You have a wide professional experience that goes from financial adviser to biotechnology entrepreneur, passing through software business and politics. How will all of those different experiences enable you to…
Your interest in bioinformatics has run though your academic career and now into your business career as CEO and founder of Biomax Informatics; what was your vision for the company…
Could you give us a brief introduction to IMS’ business model? What would you say are the main challenges encountered today in the German market for IMS? IMS has been…
See our Cookie Privacy Policy Here
